secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2026-08-04T01:54:29+00:00
Accession:  0001193125-26-331207
Event type: m_and_a
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera Therapeutics completes merger with Obsidian; becomes subsidiary of Obsidian Therapeutics
--------------------------------------------------------------------------------

- Galera shareholders receive 0.7019 shares of Parent common stock per share; Legacy Obsidian shareholders receive 0.1383 shares per share.
- Post-merger ownership: Legacy Obsidian ~51.6%, PIPE investors ~47.2%, Galera ~1.2% on fully diluted basis.
- Galera shareholders receive CVRs: 80% of net proceeds from Legacy Product (tilarganine) over 5 years, 95% from Supportive-Care divestiture over 10 years.
- Galera common stock to be delisted from OTCQB; company to file Form 15 to terminate SEC registration.
- All prior directors resigned; new officers appointed (Madan Jagasia, Julie Feder, Parameswaran Hari, Dana Alexander).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312526331207/0001193125-26-331207-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312526331207/d170816d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-331207

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer